APO-FLECAINIDE TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

FLECAINIDE ACETATE

Saatavilla:

APOTEX INC

ATC-koodi:

C01BC04

INN (Kansainvälinen yleisnimi):

FLECAINIDE

Annos:

100MG

Lääkemuoto:

TABLET

Koostumus:

FLECAINIDE ACETATE 100MG

Antoreitti:

ORAL

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

CLASS IC ANTIARRYTHMICS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0116696001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2010-06-02

Valmisteyhteenveto

Page
1
of
26
PRODUCT MONOGRAPH
PR
APO-FLECAINIDE
FLECAINIDE ACETATE TABLETS USP
50 MG AND 100 MG
ANTIARRHYTHMIC AGENT
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
NOVEMBER 7, 2017
TORONTO, ONTARIO
CANADA M9L 1T9
CONTROL NO. 209512
Page
2
of
26
PR
APO-FLECAINIDE
Flecainide Acetate Tablets USP
50 mg and 100 mg
THERAPEUTIC CLASSIFICATION
Antiarrhythmic agent
ACTIONS AND CLINICAL PHARMACOLOGY
Flecainide acetate belongs to the membrane stabilizing group of
antiarrhythmic agents: it has
electrophysiologic effects characteristic of the 1C class of the
modified Vaughn-Williams
classification. It also possesses local anesthetic properties.
In single cell preparations from canine cardiac tissues (Purkinje
fibers) flecainide acetate
decreased the rate of rise (V
max
, Phase 0) of the action potential without greatly affecting its
duration; the duration of the effective refractory period was
lengthened and a small change was
observed in the slope of Phase 4 depolarization. In ventricular
muscle, some lengthening of the
action potential duration has been observed.
In man, flecainide acetate produces a dose-related decrease in
intracardiac conduction in all parts
of the heart with the greatest effect on the His-Purkinje system (H-V
conduction). Effects upon
atrioventricular (AV) nodal conduction time and intra-atrial
conduction times, although present,
are less pronounced than those on ventricular conduction velocity.
Significant effects on
refractory periods were observed only in the ventricle. Sinus node
recovery times (corrected)
following pacing and spontaneous cycle lengths are somewhat increased.
This latter effect may
become significant in patients with sinus node dysfunction (see
WARNINGS). In patients with
accessory AV connections, flecainide acetate has been shown to depress
both anterograde and
retrograde conduction over the bypass tract.
HEMODYNAMICS:
Decreases in ejection fraction, consistent with a negative inotropic
effect, have
been observed after a single administration of 200 to 250 mg of
flecainide acet